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Abstract Tumor nectosis factor (TNF) receptors are key
players in inflammation and immune regulation. A new member
of this family, termed death receptor-6 (DR6), has been
identified. Like other death receptors, DR6 is a type I
transmembrane receptor, possesses four extracellular cysteine-
rich motifs and a cytoplasmic death domain. DR6 is expressed in
most human tissues and abundant transcript was detected in
heart, brain, placenta, pancreas, thymus, lymph node and several
non-lymphoid cancer cell lines. DR6 interacts with TRADD,
which has previously been shown to associate with TNFR1.
Furthermore, ectopic expression of DR6 in mammalian cells
induces apoptosis and activation of both NF-UB and JNK.
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1. Introduction
Members of the tumor necrosis factor (TNF) receptor fam-
ily are crucial modulators of in£ammatory and cellular im-
mune responses and mediate a variety of biological functions
ranging from cell proliferation, di¡erentiation and apoptosis
to cell survival [1^7]. This family of receptors is characterized
by several extracellular, cysteine-rich motifs that compose the
ligand binding domain [2,5]. Upon ligation by their cognate
ligands, these receptors engage a number of signal transduc-
tion pathways, including apoptosis, activation of NF-UB and
JNK pathways that modulate the expression of genes involved
in the immune and stress response [5].
Within the TNF receptor family, six members have emerged
as a distinct subgroup termed death receptors; they contain a
cytoplasmic death domain and activation of these receptors
leads to engagement of components of the cell death pathway
[1,3]. Transmission of the death signal is mediated by a series
of homophilic protein-protein interactions involving the death
domain and death e¡ector domain that was originally de¢ned
as being present in the adaptor molecule FADD/MORT1 and
the death protease caspase-8 [8]. For example, when the death
receptor CD95/Fas is ligated by cognate ligand or agonist
antibody, the adaptor molecule FADD and the death pro-
tease caspase-8 are recruited to the signalling complex through
interactions involving death and death e¡ector domains, re-
spectively [8^10]. On approximation, caspase-8 undergoes an
autoactivation, initiating activation of the downstream casp-
ases, cleavage of death substrates and demise of the cell
[11^14]. In contrast to CD-95 that directly engages the
FADD-caspase-8 pathway [9,10,15,16], both TNFR1 and
death domain-3 (DR3) utilize a primary adaptor molecule
termed TRADD, around which assembles the FADD-casp-
ase-8 pathway, an NF-UB activating pathway involving the
death domain-containing Ser/Thr kinase RIP and a JNK ac-
tivating pathway that is mediated by the adaptor molecule
TRAF2 [17^23]. Finally, there exists a subsidiary death path-
way involving the death domain-containing adaptor RAIDD
that binds to caspase-2 and has been shown to be part of the
TNFR1 receptor complex, although the exact physiologic
relevance of this redundant pathway remains unclear [24,25].
Here, we report the identi¢cation and initial characteriza-
tion of DR6, a new member of the TNF receptor family
possessing a cytoplasmic death domain. DR6 induced apop-
tosis in mammalian cells and was capable of engaging the NF-
UB and JNK pathways.
2. Materials and methods
2.1. Expression constructs
DR6(42^655) and DR6 delta(42^460) were cloned into
pCMV1FLAG (IBI-Kodak) as in-frame fusions to a NH2-terminal
preprotrypsin leader sequence and FLAG tag encoded by the vector.
cDNAs were obtained by polymerase chain reaction using DNA
oligo primers for DR6: 5P-GGAAGATCTGCCAGAACAGAAGG-
CCTCGAAT-3P and 5P-CCATCTTCCTGACCTGCTGTAGTCTA-
GAGCC-3P and for DR6 delta: 5P-GGAAGATCTGCCAGAACA-
GAAGGCCTCGAAT-3P and 5P-GCCGACCACGAGCGGGCCTA-
GTCTAGAGCC-3P. Constructs encoding DR4, FADD, CD95, DR3,
TRADD, ICH1-pro, RAIDD and RIP have been described previ-
ously [15,17^19,23,26].
2.2. Apoptosis assay
Cell death assays were performed as described [15,26]. Both HeLa
and MCF7 cells were transfected using the lipofectAMINE procedure
(Life Technologies, Inc.) according to the manufacturer’s instructions.
2.3. Co-immunoprecipitation assay
In vivo interaction assays have been described elsewhere [15,26]. 293
cells were transfected by means of calcium phosphate precipitation.
2.4. NF-UB luciferase assay
NF-UB luciferase assays were done as described [15,26].
2.5. JNK activation assay
293 cells were cultured in MEM containing 10% FBS. Cells were
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plated in 6-well plates and transfected with DR6-expressing plasmid
or vector alone at 60^70% con£uence by the lipofectAMINE method
according to the manufacturer’s instructions. Forty hours post trans-
fection, cell extracts were prepared in lysis bu¡er containing 20 mM
HEPES, pH 7.4, 2 mM EDTA, 250 mM NaCl, 0.1% NP-40, 2 Wg/ml
leupeptin, 2 Wg/ml aprotinin, 1 mM PMSF, 0.5 Wg/ml benzamide,
1 mM DTT and 1 mM orthovanadate. The C-jun kinase assay was
performed by a modi¢ed method as described [27]. Brie£y, cell ex-
tracts (70 Wg) were subjected to immunoprecipitation with 0.03 Wg
anti-JNK antibody for 30 min at 4‡C. Immunocomplexes were col-
lected by incubation with protein A/G-Sepharose beads for 30 min at
4‡C. The beads were extensively washed with lysis bu¡er (4U400 Wl)
and kinase bu¡er (2U400 Wl : 20 mM HEPES, pH 7.4, 1 mM DTT, 25
mM NaCl) and the kinase reaction allowed to proceed for 15 min at
30‡C with 2 Wg GST-Jun(1^79) in 20 Wl containing 20 mM HEPES,
pH 7.4, 10 mM MgCl2, 1 mM DTT and 10 WCi [Q32P]ATP. Reactions
were stopped by the addition of 15 Wl SDS-sample bu¡er and resolved
by SDS-polyacrylamide gel electrophoresis. GST-Jun(1^79) was vis-
ualized by staining with Coomassie blue and the dried gel visualized
following Phosphorimager analysis (Molecular Dynamics; Sunnyvale,
CA) and quantitation by ImageQuant Software (Molecular Dynam-
ics). For the JNK activity assay shown in Fig. 4B, 3U106 293 cells
were co-transfected with the indicated constructs (6.4 Wg) together
with 2.4 Wg of a JNK-myc expression plasmid. After transfection
(approximately 36 h), cell extracts were prepared by lysis in NP40
bu¡er (20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glycerol,
2 mM EDTA, 5 mM Na2VO4, 0.5 mM PMSF and 1% NP40) plus
protease inhibitor cocktail (BMB). Immunoprecipitation of JNK-myc
was done using monoclonal anti-myc antibody (10 Wg, Babco) and
immunocomplexes precipitated with 20 Wl protein G-Sepharose (50%
slurry, Sigma). The kinase assay utilized 2 Wg GST-Jun(1^79) as sub-
strate, 50 mM ATP and 5 WCi [Q32P]ATP in 30 Wl kinase bu¡er (30
mM HEPES, pH 7.4, 7 mM MnCl2, 5 mM MgCl2 and 1 mM DTT).
3. Results and discussion
3.1. Identi¢cation and molecular cloning of a new member of
the TNF receptor family
To identify additional TNF receptor-related molecules, we
searched an expressed sequence tag (EST) database using the
protein sequence of the extracellular, cysteine-rich, ligand
binding domain of TNFR2 [28,29]. Several human EST
cDNA clones were initially identi¢ed. Analyses of these clones
revealed one that contained an open reading frame encoding a
protein of 655 amino acids (Fig. 1A). Database searches, pro-
tein sequence alignment, and comparative analyses indicated
this molecule to be a novel cell surface receptor related to the
TNF receptor family and possessing an intracellular death
domain (Fig. 1C). Thus, this new molecule was named death
receptor 6, or DR6 (see below).
DR6 had a putative signal sequence (amino acids 1^41),
with the mature form predicted to start at amino acid 42
(Gln) [30]. The extracellular portion (amino acids 67^211)
contains four TNFR-like cysteine-rich motifs that are most
related to those of osteoprotegerin (OPG) and TNFR2 with
36% and 42% amino acid identities, respectively (Fig. 1B;
data not shown). A transmembrane domain (amino acids
351^370) is followed by a 285 amino acids long cytoplasmic
portion of the molecule that contains a death domain related
to those of all known death receptors (Fig. 1C), being most
related to the death domain of TNFR1 (27.2%) and least like
that of DR5 (19.7%). Curiously, unlike other death receptors
that have death domains present in their COOH-terminus, the
death domain in DR6 was located adjacent to the transmem-
brane domain followed by a 150 amino acid tail. Interestingly,
following the death domain was a putative leucine zipper se-
quence overlapping with a proline-rich region, reminiscent of
a SH3 domain-binding motif (Fig. 1A) [31]. Their functional
relevance remains to be discovered.
3.2. DR6 mRNA expression in human tissues and cancer cell
lines
A 4 kb DR6 transcript was found in most tissues (Fig. 1D).
The transcript was abundant in heart, brain, placenta, pan-
creas, lymph node, thymus, and prostate. Lower levels were
detected in lung, skeletal muscle, kidney, testis, uterus, small
intestine, colon, spleen, bone marrow, and fetal liver. How-
ever, adult liver and peripheral blood leukocytes expressed
little DR6 mRNA. Additionally, smaller transcripts of 3.1
and 2.4 kb were observed in the testis and fetal liver, respec-
tively.
Among human cancer cell lines, abundant transcript levels
were detected in several non-lymphoid tumor cells, including
cervical carcinoma HeLa S3, colorectal adenocarcinoma
SW480, lung carcinoma A549, and melanoma G361 cells. Sig-
ni¢cantly, little or no expression was observed in lines of
hematopoietic origin (Fig. 2D).
3.3. DR6 induces apoptosis in mammalian cells
Since ectopic expression of death receptors can induce cell
death in a ligand-independent manner [15,16,19,20,26], we
tested if DR6 could induce apoptosis upon overexpression.
When HeLa S3 cervical carcinoma cells were transfected
with a DR6-expressing construct, 43% of the transfected cells
underwent morphological changes characteristic of apoptosis
(Fig. 2A). As expected, deletion of the putative death domain
(DR6 delta) abolished its killing activity. Signi¢cantly, DR6
was unable to induce cell death in human breast carcinoma
MCF7 cells, although they were very sensitive to DR4 killing
(Fig. 2A and not shown), suggesting that the cell death path-
way engaged by DR6 may be distinct from that engaged by
other death receptors. Alternatively, the apoptotic activity of
DR6 may be modulated by other signaling pathways it acti-
vates (see below) or ligand binding may be required to unveil
its full killing capacity. Further work will be needed to ad-
dress this issue.
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Fig. 1. Predicted amino acid sequence of DR6. A: The open reading frame for DR6 de¢nes a type I transmembrane protein of 655 amino
acids. The GenBank accession number for the sequence: AF068868. The mature protein is predicted to start at amino acid 42 (Gln, indicated
by a black triangle). The putative signal peptide and transmembrane domain are single and double underlined, respectively. Six potential N-
glycosylation sites are indicated by black dots. The cytoplasmic death domain is boxed. An intracellular region containing a potential leucine-
zipper motif overlapping with a proline rich sequence is underlined with a thick line. B: Sequence alignment of extracellular cysteine-rich do-
mains. Alignment was done with Megalign (DNASTAR) software. Shading represents identical residues. C: Sequence comparison of death do-
mains. Alignment was done and represented in the same way as in B. OPG, osteoprotegerin. D: Tissue distribution of DR6. Human adult tis-
sue, immune tissue and cancer cell line Northern (RNA) blots (Clontech) were probed with DR6 cDNA according to the manufacturer’s
instructions. The blots were subsequently probed with L-actin cDNA (not shown). The smaller transcripts in testis and fetal liver are indicated
by black arrows. Sk. mus., skeletal muscle; Sm. int., small intestine; PBLs, peripheral blood leukocytes; LN, lymph node; BM, bone marrow,
FL, fetal liver; HL-60, promyelocytic leukemia; Hela S3, HeLa cell line; K562, chronic myelogenous leukemia; MOLT-4, lymphoblastic leuke-
mia; Raji, Burkitt’s lymphoma; SW480, colorectal adenocarcinoma; A549, lung carcinoma; G361, melanoma.
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3.4. Interaction of DR6 with adaptor molecules in vivo
Death receptors utilize the adaptor molecules FADD (for
CD95) or both TRADD and FADD (for TNFR1 and DR3)
to transmit the death signal [15,16,19,20]. We thus determined
if DR6 could bind any of these adaptor molecules in human
embryonic kidney 293 cells. DR6 did not interact with
FADD, although the association between CD95 and FADD
was readily detected under similar conditions (Fig. 2B). Inter-
estingly, DR6 was found to associate with TRADD, although
the interaction was weaker than that between DR3 and
TRADD (Fig. 2C). This observation is consistent with the
observation that DR6 has a weaker killing ability. Alterna-
tively, DR6 may use a TRADD-related molecule as an adap-
tor, or the observed association might be bridged by another
adaptor protein. Interaction was not detectable between DR6
and RAIDD or RIP, two other adaptor molecules known to
be recruited to the TNFR1 and DR3 signalling complexes
(Fig. 2D,E).
3.5. DR6 activates NF-UB
Both TNFR1 and DR3 can engage a signal transduction
pathway that leads to the activation of NF-UB [5,19,20,28].
The ability of DR6 to activate NF-UB was tested in a lucifer-
ase reporter assay and was found to induce NF-UB activation
in a dose-dependent manner (Fig. 3, left). Presumably over-
expressing the receptor allowed it to achieve an active con¢g-
uration that was competent to signal the NF-UB system. In-
terestingly, the cytoplasmic deletion of DR6 that abolished its
apoptotic activity similarly abrogated its ability to activate
NF-UB (Fig. 3, right), suggesting that these two signaling
pathways may be mediated by a common receptor-proximal
adapter molecule.
3.6. Ectopic expression of DR6 induces JNK activation
JNK activation is known to be induced by several TNF
receptors including TNFR1 and CD40 [5,21,22,28]. We next
determined whether overexpression of DR6 could lead to
JNK activation using an in vitro kinase assay. DR6 was
found to induce JNK activation in a dose-dependent manner
(Fig. 4A). The cytoplasmic truncation that attenuated cell
death or NF-UB activation had surprisingly little e¡ect on
JNK activation (Fig. 4B). This would be consistent with the
notion that JNK activation is mediated by a cytoplasmic seg-
ment di¡erent from that responsible for apoptosis and NF-UB
induction. It is noteworthy that two potential TRAF-binding
motifs are present adjacent to the transmembrane domain
(PRQDP, amino acids 381^385 and PTQNR, amino acids
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Fig. 4. DR6 induces JNK activation in mammalian cells. A: Trans-
fections of 293 cells were done with the indicated amounts of DR6-
expressing plasmid or a vector control using the lipofectamine meth-
od. After transfection (at 40 h), cell extracts were prepared and as-
sayed for JNK activity as described in Section 2. B: Cotransfection
of 293 cells was performed with the indicated constructs together
with JNK-myc-expressing plasmid using the calcium phosphate pre-
cipitation method. Thirty-six hours post transfection, cell lysates
were prepared and assayed for JNK activity as described in Section
2. JNK-myc was immunoprecipitated with anti-myc and detected by
blotting with anti-myc-HRP (BMB, bottom panel). FLAG-tagged
CD-40, DR6 and DR6 delta were immunoprecipitated with anti-
FLAG M2 a⁄nity gel and detected by blotting with anti-FLAG
antibody (not shown).
Fig. 3. DR6 mediates NF-UB activation. Cotransfection of 293 cells
was performed with the indicated expression constructs and a NF-
UB luciferase reporter construct. After transfection (at 36 h), cell ex-
tracts were prepared and luciferase activities determined as described
[19,26]. Transfection e⁄ciency was monitored by L-galactosidase ac-
tivity. A portion of the transfected cells was used to monitor expres-
sioin of DR6 or DR6 delta (not shown). 2 Wg of each DNA con-
struct was used for the luciferase assays shown on the left.
Fig. 2. DR6 induces apoptosis in mammalian cells. A: Ectopic expression of DR6 induces apoptosis in HeLa cells, but not in MCF7 cells.
HeLa and MCF7 cells were cotransfected with an empty vector, DR6, DR6 delta or DR4 together with a L-galactosidase-expressing reporter
construct using a lipofectamine method according to the manufacturer’s instructions (BRL). Nineteen hours after transfection, cells were stained
with 5-bromo-4-chloro-3-indoxyl-L-D-galactopyranoside (X-Gal) and examined [15]. The data (mean þ S.D.) represent the percentage of round,
apoptotic cells as a function of total L-galactosidase-positive cells (n = 4). B: Interaction of DR6 with adapter molecules. 293 cells were cotrans-
fected with the indicated expression constructs using a calcium phosphate precipitation method. After transfection (at 38^40 h), cell lysates
were prepared and the FLAG-tagged death receptors immunoprecipitated with FLAG M2 a⁄nity gel (IBI-Kodak) and the presence of FADD,
myc-tagged TRADD and RIP (myc-TRADD and myc-RIP), or RAIDD detected by immunoblotting with polyclonal antibody to FADD,
horseradish peroxidase (HRP)-conjugated antibody to myc (BMB), or polyclonal antibody to RAIDD, respectively. Numbers to the left of the
gels indicate molecular sizes in kilodaltons.
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400^404) [32^34]. Mutational analysis will be required to
understand their functional signi¢cance.
In conclusion, we have identi¢ed a novel death domain-
containing TNF receptor designated DR6. DR6 engages a
cell death pathway di¡erent from those initiated by the
CD95, TNFR1 or TRAIL/Apo2L receptors. In addition,
DR6 also activates NF-UB and JNK, two signaling pathways
shared by TNFR1. Although its physiological function is un-
known, it is probable that, like the other members of the TNF
receptor family, DR6 may play a role in in£ammatory re-
sponses and immune regulation. Identi¢cation of the ligand
and targeted gene disruption will further our understanding of
the physiologic role of this new member of the TNF receptor
family.
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